← Back to mCPP

mCPP Stats & Data

Stimulant Research-chemical

Cpp 3-cpp Meta-chlorophenylpiperazine

PubChem CID 1355

PubChem

MW214.64

FormulaC10H11ClO3

LogP3.1

IUPAC2-(4-chloro-2-methylphenoxy)propanoic acid

SMILESCC1=C(C=CC(=C1)Cl)OC(C)C(=O)O

InChIKeyWNTGYJSOUMFZEP-UHFFFAOYSA-N

Chemical Class Phenylpiperazine

Psychoactive Class Stimulant

Pharmacology

DrugBank

Description

m-Chlorophenylpiperazine has been used in trials studying the treatment of Alcoholism.

Receptor Profile

Receptor Actions

Agonists

5-HT2B receptor partial agonist

5-HT2C receptor partial agonist

Antagonists

5-HT2A receptor antagonist

Inhibitors

Serotonin reuptake inhibitor

Other

Serotonin releasing agent

Receptor Binding

serotonin reuptake inhibitor

Measured Affinities

Guide to PHARMACOLOGY

Measured binding and functional data for m-chlorophenylpiperazine, curated by the IUPHAR/BPS Guide to PHARMACOLOGY. Each row cites the paper it came from. Lower concentrations mean tighter binding — a value in the sub-nanomolar range indicates a very potent interaction.

Target	Action	Measure	Value	Concentration	Species	Source
5-HT2B receptor Htr2b	Partial agonist	pKi	7.6	25.12 nM	Rat	PMID 8450835
5-HT2C receptor Htr2c	Partial agonist	pKi	7.2	63.1 nM	Rat	PMID 11104741
5-HT1D receptor HTR1D	Antagonist	pKi	6.7	199.53 nM	Human	PMID 1652050
5-HT2A receptor Htr2a	Partial agonist	pKi	6.4	398.11 nM	Rat	PMID 11104741
5-HT6 receptor Htr6	Full agonist	pKi	5.6	2,512 nM	Rat	PMID 7680751
5-ht1e receptor HTR1E	Partial agonist	pKi	5.4	3,981 nM	Human	PMID 14744596
5-HT2A receptor HTR2A	Partial agonist	pKi	—	—	Human	—
5-HT2B receptor HTR2B	Partial agonist	pKi	—	—	Human	—
5-HT2C receptor HTR2C	Partial agonist	pKi	—	—	Human	—
5-HT7 receptor Htr7	Full agonist	pKi	—	—	Rat	PMID 8394362

Reading this. pKi, pEC50 and pIC50 are negative log molar values, so a higher number means a tighter interaction; the concentration column converts them for you. Values from non-human species are laboratory measurements and do not translate directly to human effect. Receptor affinity is not a dose — it describes what a molecule binds, not how much of it is safe to take.

Receptor data from the IUPHAR/BPS Guide to PHARMACOLOGY (v2026.2), licensed CC BY-SA 4.0. Matched to this substance by InChIKey.

Toxicity

PsychonautWiki

It is strongly recommended that one use harm reduction practices when using this drug.

Effect Profile

Curated + 3 Reports

Stimulant 4.1

Moderate stimulation with strong anxiety/jitters, mild euphoria

Stimulation / Energy×3

Euphoria / Mood Lift×2

Focus / Productivity×2

Anxiety / Jitters×1

Based on reports from:

Erowid Experience Reports PsychonautWiki mCPP

Tolerance & Pharmacokinetics

drugs.wiki

Tolerance Decay

Full tolerance 1d Half tolerance 10d Baseline ~18d

Experience Report Analysis

Erowid

7 Reports

3 Single-substance

2005–2009 Date Range

1 With Age Data

2 Effects Detected

Demographics

Gender Distribution

Too few reports for a chart: gender is known from 7 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

Male 7 of 7

Age Distribution

Reports Over Time

Effect Analysis

Erowid

Effects aggregated from 3 experience reports (3 single-substance Erowid)

3 Reports

2 Effects Detected

1 Positive

1 Adverse

0 Neutral

Effect Sentiment Distribution

Confidence Distribution

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Too few reports for bars: these effects come from 3 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

Positive Effects 1

Euphoria 3 of 3 70%

Adverse Effects 1

Anxiety 3 of 3 70%

Also reported in combinations. In the 4 mCPP reports where another drug was taken too, 0 mention hospital, emergency services or an overdose, 1 a seizure and 1 psychosis (too few reports for percentages). In the 3 single-substance reports: 0, 0 and 0. These are not in the figures above: they cannot be put down to mCPP alone, and a mention is not always something that happened to the writer.

Form / Preparation

Most common forms and preparations, as a share of the 4 reports that give one

Too few reports for bars: these forms come from 4 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

Pill / Tablet 3 of 4

Read full reports on Erowid →

Legal Status

Country	Status	Notes
Austria	Since January 1, 2012, mCPP is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
Belgium	mCPP is a controlled substance as of October 22, 2006.
Brazil	mCPP is a controlled substance ( lista F2 da Portaria SVS/MS 344/98 ) since November 2008.
China	As of October 2015, mCPP is a controlled substance in China.
Denmark	mCPP is a controlled substance as of December 3, 2005.
Finland	mCPP is a controlled substance.
Germany	mCPP is controlled under Anlage II BtMG ( Narcotics Act, Schedule II ) as of March 1, 2007.	It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Greece	mCPP is a controlled substance as of January 20, 2005.
Hungary	mCPP is a controlled substance as of January 1, 2006.
Japan	mCPP is a controlled substance since 2006.
Lithuania	mCPP is a controlled substance as of July 1, 2006.
Norway	mCPP is a controlled substance.
Poland	mCPP is a controlled substance.
Russia	mCPP is a controlled substance.
Sweden	mCPP is a controlled substance.
Switzerland	mCPP is a controlled substance specifically named under Verzeichnis D.
United Kingdom	mCPP is a Class C, Schedule 4 (Part 1) drug in the United Kingdom.
United States	mCPP is unscheduled in the United States, but could be considered an analogue of benzylpiperazine if it is sold for human consumption.

References

Data Sources

Cited References

← Back to mCPP